KAER Biotherapeutics develops advanced aerosol delivery systems designed to enable effective pulmonary deposition of inhaled complex therapeutics for patients with respiratory disease.
AeroPulsR™ Base and AeroPulsR™ Programmable comprise KAER’s aerosol delivery platform. These systems are designed to deliver high concentrations of respirable aerosols from complex formulations that include surfactants, biologics, and antibiotics while preserving biological activity. The platform supports controlled delivery across neonatal, pediatric, and adult patients within critical care settings.
AeroPulsR enables delivery of emerging therapeutic classes, including viscous and biologically sensitive agents, by providing controlled, reproducible aerosol delivery at clinically relevant levels. This capability supports the advancement of inhaled therapies where consistent pulmonary deposition is required to achieve therapeutic outcomes.
KAER works with pharmaceutical companies and CDMOs to support evaluation, development, and integration of aerosol delivery into therapeutic programs. This collaborative approach enables partners to advance inhaled applications across a range of respiratory indications.
KAER’s work is driven by the need to improve outcomes for patients with respiratory disease in both the United States and worldwide, where effective delivery of inhaled therapeutics remains essential to clinical care.
KAER Biotherapeutics
926 S. Andreasen Drive
Suite 105
Escondido, CA 92029-1939
USA
760 480 9400
www.kaerbio.com
dyeates@kaerbio.com
AeroPulsR™ Programmable
AeroPulsR Programmable is a high-performance aerosol platform engineered for controlled, high concentration delivery of complex therapeutics to the lung. It supports continuous, periodic, and breath-synchronized delivery modes, enabling precise control of dose timing and exposure. The system generates respirable aerosols with narrow size distribution while maintaining formulation integrity across a wide range of viscosities and biologics. Adjustable output rates and integrated control architecture enable tailored therapy delivery and advanced research applications and spontaneously breathing patients across all age groups.
More Info
AeroPulsR™ Base
AeroPulsR Base is a fixed-parameter aerosol delivery system designed for consistent pulmonary administration of liquid formulations. The system operates with a simple start/stop interface under internally controlled conditions, minimizing variability and enabling rapid deployment. Compatible with a wide range of aqueous and colloidal formulations, it supports continuous aerosol output with low residual volume, making it well-suited for standardized delivery in clinical and research environments.
More Info
SUPRAER™
SUPRAER is a solid-phase aerosol generation and delivery platform that converts aqueous formulations into high-concentration, respirable dry aerosols in a single stage. Using a proprietary spray-drying and virtual impactor concentration system, it delivers uniform, high dose-rate aerosols with controlled particle size (1.5–4 µm MMAD). The platform supports a wide range of agents, including biologics, polymers, and nanoparticles, without requiring complex formulations or excipients. SUPRAER enables efficient, repeatable aerosol delivery for inhalation toxicology, drug development, and high-dose pulmonary applications, with significantly increased drug mass per particle and reduced inhalation time.
More Info
